Palisade Bio, Inc.

NasdaqCM PALI

Palisade Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

Palisade Bio, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Palisade Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 15.31 M.
Palisade Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 14.10 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: PALI

Palisade Bio, Inc.

CEO	Mr. J. D. Finley
IPO Date	March 30, 2007
Location	United States
Headquarters	5800 Armada Drive
Employees	9
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Dental Care Non-Alcoholic Beverages Pet Food Vaccines

Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Key trends

Past 5 years